Comparison of Efficacy of Colchicine Plus Dual Antiplatelet Therapy vs. Dual Antiplatelet Therapy Alone in Patients with Acute Myocardial Infarction Undergoing Primary PCI
DOI:
https://doi.org/10.51253/pafmj.v76iSUPPL-4.14166Keywords:
Colchicine, Dual antiplatelet therapy, Major Adverse Cardiovascular Events, Primary Percutaneous Coronary Intervention.Abstract
Objective: To evaluate the impact of colchicine on inflammatory markers, left ventricular function, and major adverse cardiovascular events (MACE) over 3 months.
Study Design: Quasi experimental study.
Place and Duration of Study: Cardiology Department of Armed Forces Institute of Cardiology, National Institute of Heart Diseases, Rawalpindi Pakistan, from Jun 2025 to Oct 2025.
Methodology: Two hundred fifty-nine Acute Myocardial Infarction (AMI) patients undergoing primary percutaneous coronary intervention (PPCI) were enrolled through nonprobability consecutive sampling with non-random allocation into two groups: Experimental-Group 127 received colchicine + Dual Antiplatelet Therapy (DAPT), and Control-Group 132 received DAPT alone. The endpoints were changes in C-reactive protein (CRP) and left ventricular ejection fraction (LVEF) and MACE.
Results: Out of 259, mean age was 63.11±10.63 years in the Colchicine-Group and 60.43±11.01 years in the non-Colchicine-Group, with males comprising 90.6% and 84.1% of participants, respectively. Baseline characteristics were similar between groups. No statistically significant differences were found in CRP levels or LVEF at 1 and 3 months. At 3 months, MACE rates—including mortality (0% vs 1.5%), recurrent MI (0% vs 0.8%), heart failure (0.8% vs 0.7%), and stent thrombosis (0.8% vs 0.7%)—showed no significant difference between colchicine and control groups.
Conclusion: In AMI patients undergoing primary PCI, adding colchicine to DAPT did not significantly reduce inflammatory markers, improve left ventricular function, or decrease MACE over 3 months. Larger randomized controlled trials with longer follow-up are recommended.
Downloads
References
1. Salatzki J, Giannitsis E, Hegenbarth A, Mueller-Hennessen M, André F, Frey N, et al. Absence of visible infarction on cardiac magnetic resonance imaging despite the established diagnosis of myocardial infarction by 4th Universal Definition of Myocardial Infarction. European Heart Journal: Acute Cardiovascular Care 2024; 13(1): 24-35.
https://doi.org/10.1093/ehjacc/zuad128
2. Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin J, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention: the COLCHICINE-PCI randomized trial. Circ Cardiovasc Interv 2020; 13(11): e008523.
https://doi.org/10.1161/CIRCINTERVENTIONS.119.008717
3. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381(26): 2497-2505.
https://doi.org/10.1056/NEJMoa1912388
4. Caesario F, Prasetya I, Rohman MS, Satrijo B, Anjarwani S. Effects of the low-dose colchicine regimen on left ventricular adverse remodeling and systolic function in acute myocardial infarction patients with anterior ST-segment elevation undergoing primary percutaneous coronary intervention: a randomized controlled trial. Heart Sci J 2024; 5(2): 51–56:
https://doi.org 10.21776/2024.005.02.9
5. Banco D, Mustehsan M, Shah B. Update on the Role of Colchicine in Cardiovascular Disease. Curr Cardiol Rep 2024; 26(4): 191-198.
https://doi: 10.1007/s11886-024-02026-5
6. Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation 2020; 142(20): 1890-1900.
https://doi.org/10.1161/CIRCULATIONAHA.120.050771
7. Akhtar A, Saleemi MS, Zarlish QM, Arshad MB, Hashmi KA, Ghafoor H. Experience and Outcomes of Primary Percutaneous Coronary Intervention in a Tertiary Care Hospital in South Punjab, Pakistan. Cureus 2023; 15(12): e50024.
https://doi.org/10.7759/cureus.50024
8. Domienik-Karłowicz J, Kupczyńska K, Michalski B, Kapłon-Cieślicka A, Darocha S, Dobrowolski P, et al. Fourth universal definition of myocardial infarction: selected messages from the European Society of Cardiology document and lessons learned from the new guidelines on ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome. Cardiol J 2021; 28(2): 195-201..
https://doi.org/10.5603/CJ.a2021.0036
9. Vaidya K, Arnott C, Martínez GJ, McCormack S, Sullivan D, Patel S. Colchicine therapy in acute coronary syndrome: a systematic review and meta-analysis. Heart Lung Circ 2015; 24(6): 556-562.
10. Singh S, Fong HK, Desai R, Zeng Z, Rodriguez AP, Savani C, et al. Meta-analysis of colchicine use in acute and chronic coronary disease. Am J Cardiol 2020; 125(6): 925-931.
11. Bytyçi I, Bajraktari G, Penson PE, Henein MY, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP). Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2022; 88(4): 1520-1528.
https://doi.org/10.1111/bcp.15041
12. Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Euro Heart J 2020; 41(42): 4092-4099.
https://doi.org/10.1093/eurheartj/ehaa659
13. Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, et al. The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J 2019; 215: 62-69. https://doi.org/10.1016/j.ahj.2019.06.003
14. Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine in cardiovascular disease. Atherosclerosis 2018; 269: 262-271.
https://doi.org/10.1016/j.atherosclerosis.2017.12.027
15. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39(2): 119-177.
https://doi.org/10.1093/eurheartj/ehx393
16. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy. Circulation 2016; 134(10): e123-155.
https://doi.org/10.1016/j.jacc.2016.03.513
17. Su ST, Lee YH, Wei JC. Colchicine in Cardiovascular Disease: Mechanisms of Action and Therapeutic Potential. International Journal of Rheumatic Diseases 2025; 28(1).
https://doi.org/10.1111/1756-185X.70081
18. Finocchiaro S, Mazzone PM, Ammirabile N, Bordonaro C, Cusmano C, et al. Anti-inflammatory pharmacotherapy in patients with cardiovascular disease. European Heart Journal‐Cardiovascular Pharmacotherapy 2025; 11(8): 712-728.
https://doi.org/10.1093/ehjcvp/pvaf058
19. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). N Engl J Med 2017; 377(12): 1119-1131.
Downloads
Published
License
Copyright (c) 2026 Muhammad Ameen, Ali Nawaz , Hafiz waleed Khan , Sobia Mehreen , Muhammad Adil, Muhammad Asad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
